CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, today announced the presentation of positive pre-clinical data for ALTU-237 at the American Society of Nephrology’s (ASN) Renal Week annual meeting. The ALTU-237 presentation title was “Crystalline Formulation of an Orally Administered Oxalate Degrading Enzyme Reduces Hyperoxaluria in a Mouse Genetic Model.” The pre-clinical results showed that four weeks of therapy with ALTU-237 resulted in a sustained reduction of urinary oxalate in an animal model with primary hyperoxaluria. The ALTU-237 data was presented at one of ASN’s symposia session titled “Renal Stones: Another Hard Topic,” which was held on Sunday, November 19, 2006.
